breath holding spell. Other and unspecified abnormalities of breathing
Conditions
Interventions
Intervention 1: Intervention group: administration of piracetam in 6 mounth period with dose of 40/mg/kg/day. Intervention 2: contorol group: administration of placebo in 6 mounth period.
Treatment - Drugs
Placebo
Intervention group: administration of piracetam in 6 mounth period with dose of 40/mg/kg/day
contorol group: administration of placebo in 6 mounth period
Sponsors
Ardeabil University of Medical Sciences.
Eligibility
Sex/Gender
All
Age
1 Years to 14 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1)Parental consent for participation in the plan 2) Normal EEG 3) absent of systematic disease 4) Normal growth and Development 5)History of breath- Holding spell and physical and neurological examination by pediatric neurologist. 6) No Electrolyte Abnormality (Hypoglycemia and Hypocalcaemia ) Exclusion criteria: 1) Children with history of convulsion 2) Children that received Anticonvulsant drugs. 3) Delayed neurotic development 4) all Children with heart diseases 5) all children with anemia 6) Side effects of priacetam including true dizziness, convulsion, extra pyramidal sings, lethargy, headache, sleepiness; gastrointestinal complication including nausea and vomiting, diarrhea, constipation, anorexia, increased weight
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Interval time between BHS. Timepoint: before prevention and every 2 month in 6 month. Method of measurement: questionnaire & exam.;BHS duration. Timepoint: before prevention and every 2 month in 6 month. Method of measurement: Filling a questionnarie by asking questions from parents & exam. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Mehrdad Mirzarahimi
Ardebil University of Medical Sciences
Outcome results
None listed